
This image represents the drug.
In blue is the antibody, which provides targeting to tumors. The antibody finds the protein TM4SF1, which is predominantly located in tumors, and binds to it.
In yellow is the conjugated drug payload, which endows the antibody with efficacy. AGX101’s payload is toxic to dividing cells, and is intended to kill cells in the tumor.
TM4SF1 has several features that make it attractive as a cancer target. It is expressed in two parts of the tumor, the tumor vasculature and the tumor cells. In the tumor vessels, TM4SF1 enables angiogenesis, the process by which tumors grow their blood supply. In tumor cells, TM4SF1 enables invasion and metastasis. Angiogenesis, invasion, and metastasis are hallmarks of cancer that are substantially responsible for its lethality.